Loading…

Effects of intravenous tranexamic acid on bleeding during burn surgery: A double-blinded randomized clinical trial

Blood loss during burn surgery significantly contributes to morbidity and mortality. Tranexamic acid (TXA), an antifibrinolytic agent, is hypothesized to reduce intraoperative bleeding. This double-blinded, randomized clinical trial aimed to assess the efficacy of systemic TXA in severe burn patient...

Full description

Saved in:
Bibliographic Details
Published in:Burns 2025-02, Vol.51 (1), p.107270, Article 107270
Main Authors: Naderi, Mohsen Abaspour, Moghadam, Anoush Dehnadi, Mobayen, Mohammadreza, Rimaz, Siamak, Haghani-Dogahe, Zahra, Roudsarabi, Sajjad, Tolouei, Mohammad, Zarei, Reza
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Blood loss during burn surgery significantly contributes to morbidity and mortality. Tranexamic acid (TXA), an antifibrinolytic agent, is hypothesized to reduce intraoperative bleeding. This double-blinded, randomized clinical trial aimed to assess the efficacy of systemic TXA in severe burn patients (total body surface area [TBSA] > 20 %) undergoing surgery. The study evaluated the impact of TXA on surgical bleeding, operating room (OR) time, intravenous (IV) fluid requirements, length of hospital stay (LOS), and overall patient outcomes. A total of 94 patients, with equal distribution in age, sex, and TBSA, were randomly assigned into two groups (47 each). We administered TXA as a 10 mg/kg loading dose followed by a 1 mg/kg/h infusion during surgery. Results demonstrated significant reductions in blood loss (P = 0.043), total IV fluid volume (P = 0.021), OR time (P = 0.002), LOS (P = 0.0001), and transfusions (P = 0.024) in the TXA group. Notably, women and patients without inhalation injuries exhibited better responses to TXA treatment, and graft survival was lower in the TXA group. The study concludes that IV TXA administration during burn surgery can reduce bleeding, minimize IV fluid and blood transfusion needs, and shorten surgery duration, enhancing overall surgical outcomes. •Intravenous tranexamic acid can reduce bleeding during burn surgeries.•Operating time, intravenous fluid and transfusion is minimized in burn surgeries with tranexamic acid administration.•Women tend to bleed less during burn surgeries compared to men when using systemic tranexamic acid.
ISSN:0305-4179
1879-1409
1879-1409
DOI:10.1016/j.burns.2024.09.009